- Home
- PFSI vs GH Comparison
PFSI vs GH Comparison
Compare PFSI & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFSI | GH |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 14.1B |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PFSI | GH |
|---|---|---|
| Price | $130.48 | $101.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $138.67 | $82.76 |
| AVG Volume (30 Days) | 330.5K | ★ 2.2M |
| Earning Date | 01-29-2026 | 10-29-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ 191.00 | N/A |
| EPS | ★ 9.30 | N/A |
| Revenue | ★ $2,723,457,000.00 | $902,569,000.00 |
| Revenue This Year | $5.53 | $34.72 |
| Revenue Next Year | $29.51 | $26.46 |
| P/E Ratio | $14.03 | ★ N/A |
| Revenue Growth | 21.25 | ★ 30.38 |
| 52 Week Low | $85.74 | $29.91 |
| 52 Week High | $136.62 | $112.43 |
Technical Indicators
Market Signals| Indicator | PFSI | GH |
|---|---|---|
| Relative Strength Index (RSI) | 52.66 | 55.40 |
| Support Level | $127.84 | $100.21 |
| Resistance Level | $133.51 | $109.59 |
| Average True Range (ATR) | 3.20 | 4.22 |
| MACD | -0.35 | -1.65 |
| Stochastic Oscillator | 39.79 | 13.51 |
Price Performance
Historical ComparisonAbout PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.